Close

MIDAS
Online Portal for COVID-19 Modeling Research

Information and Resources for COVID-19 Modeling Research

Since late December 2019, a new Coronavirus infectious disease (COVID-19) has spread around the world. This global outbreak has been characterized as a pandemic by the World Health Organization. Researchers, students, and others in the Models of Infectious Disease Agent Study (MIDAS) create and use computational models to study transmission dynamics of a broad range of infectious diseases. Many MIDAS members are conducting research on COVID-19 and are contributing to an extraordinary international collection of data and information regarding the outbreak.
For general guidance and information about the global COVID-19 situation, follow information by the World Health Organization.
For guidance on the U.S. situation, see the U.S. CDC COVID-19 website.
For journalists and the general public, see the Software Catalog for a list of dashboards and visualizations to follow the COVID-19 pandemic.
For researchers and others interested in COVID-19 data and parameter estimates, see the Data and Information section.
For questions or ideas regarding COVID-19 modeling research, contact questions@midasnetwork.us.

COVID-19 General Announcements

COVID-19 modeling expert survey seeking participants

Since mid-February, Tom McAndrew and Nicholas Reich at UMass-Amherst have been surveying expert modelers (many from the MIDAS network) about the trajectory of the COVID-19 outbreak. The experts’ responses have been aggregated into “consensus opinions” from the modeling community and shared with decision-makers at CDC and the White House. Recent reports are available here and here. The more participation we have in this effort, the broader a range of views it will represent and we believe the more useful and accurate the results will be. Surveys are sent out weekly, typically have 5-6 items, and require 5-10 minutes to complete. Many thanks to those of you who have participated already! If you are interested in participating in future surveys, please email Tom McAndrew at mcandrew@umass.edu indicating your interest.

High Performance Computing (HPC) Resources Available

The NSF-funded XSEDE HPC resource is available for COVID-19 modeling by infectious disease modelers working together with the US Centers for Disease Control and Prevention, fee of charge. XSEDE provides large HPC capacity funded by the National Science Foundation (NSF). Interested researchers can contact the Principal Investigator of XSEDE, John Towns at the University of Illinois directly (jtowns@ncsa.illinois.edu).  

Online Stanford COVID-19 Meeting scheduled for April 1st

The Stanford Human-Centered AI (HAI) institute is organizing a pop-up ONLINE and distributed meeting on “Covid-19: challenges for AI, data science and informatics” for April 1, 2020. Interested researchers and students interested in participating can contact Dr. Russ Altman, Associate Director of HAI (Russ.Altman@stanford.edu).

COVID-19 Funding Announcements

National Science Foundation (NSF) RAPID Funding

NSF General COVID-19 RAPID Funding Announcement

In light of the emergence and spread of the coronavirus disease 2019 (COVID-19) in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.


NSF Office of Advanced Cyberinstrastucture participates in NSF RAPID funding for COVID-19 data and software infrastructure.

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program.


NSF Mathematical Biology in the Division of Mathematical Sciences also participates in NSF COVID-19 RAPID funding for mathematical modeling of COVID-19. Contact Zhilan Feng at the NSF Mathematical Biology Program (zfeng@nsf.gov).

Wellcome Trust

Wellcome Trust – Epidemic Preparedness: COVID-19 funding call

This call aims to strengthen the evidence base to better prevent and control coronavirus (COVID-19) epidemics and to increase research and response capacity. It’s part of an existing partnership between Wellcome and the UK Department for International Development (DFID) through the Joint Initiative on Research in Epidemic Preparedness and Response to help low- and middle-income countries prepare for and tackle epidemics. There are no deadlines. Expressions of interest should be submitted as soon as possible.

National Institutes of Health (NIH)

New Notice of Special Interest Funding through NIH

This Notice of Special Interest Funding (NOSI), NOT-AI-20-030, is to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV through Urgent Competitive Revisions to Existing Supplements of an NIH grant. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens, through administrative supplements within the scope of an existing NIH grant. There are two ways to apply: through PA-18-935, which enables the expansion of the scope of an existing grant; or through PA-18-591, which enables an nCoV supplement if it is within the scope of an existing grant.

Data and Information for COVID-19 Modeling

Disclaimer: Information listed in this section has been extracted from reputable scientific sources by the MIDAS Coordination Center and community members. This information should not be considered as endorsed by the MIDAS Coordination Center or its funding agency, the U.S. National Institutes of Health. Users should decide on the validity of each dataset or parameter estimate as they would for any other source of information used for scientific research.

Dataset Catalog

Public-access data collections with documented metadata. (Click on a collection name to see the collection in GitHub.)
TypeSPATIAL COVERAGECollection NameCreator(s)
Cases line listHong KongLatest local situation of Severe Respiratory Disease associated with a Novel Infectious AgentHong Kong Center for Health Protection
Case countsSouth KoreaPress releases about nCoVKorean Centers for Disease Control
Cases line listSouth KoreaCOVID 19 South KoreaSang Woo Park
Cases line listSouth KoreaConfirmed patient movement routeKorean Centers for Disease Control
Case countsChinaDistribution of new coronavirus pneumoniaChina CDC
Case countsHubei Provincehubey early deaths 2020 07 02Dorigatti I, et al.
Case countsChinaDistribution of new coronavirus pneumoniaChina CDC
Case countsChinaNumber of cumulative cases by Chinese prefecture from DXY.cnDXY.cn
Case countsEuropeSituation update for the EU/EEA, the UK and SwitzerlandEuropean Centre for Disease Prevention and Control
Case countsGlobalNovel Coronavirus (2019 nCoV) situation reportsWorld Health Organization
Cases line listGlobalWHO Novel Coronavirus Disease Outbreak NewsWorld Health Organization
Cases line listThailandNovel Coronavirus 2019 Pneumonia SituationEmergency Operation Center, Department of Disease Control
Cases line listThailandSituation report for citizens and the mediaEmergency Operation Center, Department of Disease Control
Cases line listGlobalnCoV line listings from DXY.cn maintained by NIH FogartySun K
Cases line listGlobalinternational cases 2020 08 02Dorigatti I, et al.
Cases line listGlobalGithub repository with nCoV line listings from various sources and data processing codemaintained by Oxford and others Gutierrez B, et al.
Cases line listGlobalnCoV line listings from various sources maintained by Oxford and othersGutierrez B, et al.
Cases line listCambodiaMinistry of Health Announcement on New Case of Coronavirus in Preah Sihanouk Province (2019 nCoV)Cambodia Ministry of Health
Case countsOntarioThe 2019 Novel Coronavirus (2019 nCoV), Status of cases in OntarioOntario Ministry of Health
Data from papersChinaThe role of absolute humidity on transmission rate of the COVID 19 outbreakLuo W, et al.
Genome dataGlobalGenomic epidemiology of novel coronavirus (nCoV)Nextstrain

Parameter Estimates - Peer-reviewed

Published estimates of epidemiological characteristics that have been peer-reviewed, encoded by community members and approved by authors. For complete information on each estimate, view this file on GitHub.
namevaluecountrylower boundupper boundstart dateend datepublication datesource
Ascertainment rate0.092Japan0.050.22020-01-222020-01-292020-02-04Nishiura H, et al.
Incubation period5.2China4.462019-12-012019-02-042020-02-04Lauer SA, et al.
Cases exported internationally from wuhan461China2278052019-12-312020-01-282020-01-31Wu JT, et al.
Cases exported internationally from wuhan113China571932019-12-312020-01-282020-01-31Wu JT, et al.
Cases exported internationally from wuhan98China491682019-12-312020-01-282020-01-31Wu JT, et al.
Cases exported internationally from wuhan111China561912019-12-312020-01-282020-01-31Wu JT, et al.
Cases exported internationally from wuhan80China401392019-12-312020-01-282020-01-31Wu JT, et al.
Cumulative case count75815China373041303302019-12-012020-01-252020-01-31Wu JT, et al.
Basic reproduction number2.24China1.962.552020-01-102020-01-242020-01-27Zhao S, et al.
Proportion of hospitalized cases that die0.14China0.0390.32Unspecified2020-01-212020-01-21Wu P, et al.
Basic reproduction number0.3China0.170.442020-01-092020-01-112020-01-12Wu P, et al.

Parameter Estimates - Not peer-reviewed

Published estimates of epidemiological characteristics that have not been peer-reviewed, encoded by community members and approved by authors. For complete information on each estimate, view this file on GitHub.

namevaluecountrylower boundupper boundstart dateend datepublication datesource
Basic reproduction number2.5Japan2.432.552020-01-142020-03-082020-03-16Sugishita Y, et al.
Effective reproduction number1.88Japan1.682.022020-01-142020-03-082020-03-16Sugishita Y, et al.
Effective reproduction number0.9Singapore0.712020-01-212020-03-052020-03-12Amna Tari, et al.
Epidemic size294.4Singapore101.11239.72020-01-212020-03-052020-03-12Amna Tari, et al.
Growth rate1.1Singapore0.422020-01-212020-03-052020-03-12Amna Tari, et al.
Overall reproductive number0.7Singapore0.512020-01-212020-03-052020-03-12Amna Tari, et al.
Dispersion parameter0.4Singapore0.1Inf2020-01-212020-03-052020-03-12Amna Tari, et al.
Basic reproduction number3.6Iran3.24.22020-02-192020-02-292020-03-10Muniz-Rodriguez K, et al.
Growth rate0.85Iran0.6912020-02-192020-02-292020-03-10Muniz-Rodriguez K, et al.
Basic reproduction number3.58Iran1.298.462020-02-192020-02-292020-03-10Muniz-Rodriguez K, et al.
Doubling time1.2Iran1.051.442020-02-192020-02-292020-03-10Muniz-Rodriguez K, et al.
Ascertainment rate0.44Japan0.370.5Unspecified2020-28-022020-03-10Omori R, et al.
Incubation period8.13China7.378.912020-01-122020-01-232020-03-10Qin J, et al.
Incubation period8.62China8.029.282020-01-122020-01-232020-03-10Qin J, et al.
Generation interval5.2Singapore3.786.782019-12-312020-02-262020-03-08Ganyani T, et al.
Serial interval5.21Singapore-3.3513.942019-12-312020-02-262020-03-08Ganyani T, et al.
Basic reproductive number1.27Singapore1.191.362019-12-312020-02-262020-03-08Ganyani T, et al.
Generation interval3.95China3.014.912019-12-312020-02-272020-03-08Ganyani T, et al.
Serial interval3.95China-4.4712.512019-12-312020-02-272020-03-08Ganyani T, et al.
Basic reproductive number1.59China1.421.782019-12-312020-02-272020-03-08Ganyani T, et al.
Incubation period6.6Singapore1.811.42020-01-192020-02-262020-03-06Tindale LC, et al.
Time from symptom onset to hospitalization5.9Singapore0.8112020-01-192020-02-262020-03-06Tindale LC, et al.
Time from hospitalization to recovery13.3Singapore7.319.32020-01-192020-02-262020-03-06Tindale LC, et al.
Incubation period5.4China0.99.92020-01-212020-02-222020-03-06Tindale LC, et al.
Time from symptom onset to case confirmation5.2China19.42020-01-212020-02-222020-03-06Tindale LC, et al.
Case fatality rate2.2ChinaUnspecifiedUnspecified2020-01-212020-02-222020-03-06Tindale LC, et al.
Incubation period7.1Singapore6.18.32020-01-192020-02-262020-03-06Tindale LC, et al.
Incubation period5.46Singapore1.3411.12020-01-192020-01-312020-03-06Tindale LC, et al.
Incubation period7.27Singapore1.3117.32020-02-012020-02-262020-03-06Tindale LC, et al.
Incubation period9China7.9210.22020-01-212020-02-222020-03-06Tindale LC, et al.
Incubation period6.9China212.72020-01-212020-01-312020-03-06Tindale LC, et al.
Incubation period12.4China5.4192020-02-012020-02-222020-03-06Tindale LC, et al.
Serial interval4.56Singapore2.696.422020-01-192020-02-262020-03-06Tindale LC, et al.
Serial interval4.22China3.435.012020-01-212020-02-222020-03-06Tindale LC, et al.
Incubation period4.8China4.25.42020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery20.3China19.421.32020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery21.2China20.222.32020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery17.5China15.3202020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery19.1China15.822.92020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery19.2China17.5212020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery19.2China1820.52020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery21.6China2023.42020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery22.4China20.824.12020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery22.9China21.224.72020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery22.5China19.126.32020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery20.1China1921.32020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery20.3China19.521.12020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery28.3China25.331.62020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery19.3China17.920.92020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery21.2China20.4222020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery21.2China1824.92020-01-142020-02-122020-03-04Qifang B, et al.
Secondary attack rate14.9China12.118.22020-01-142020-02-122020-03-04Qifang B, et al.
Secondary attack rate9.6China7.911.82020-01-142020-02-122020-03-04Qifang B, et al.
Serial interval6.3China5.27.62020-01-142020-02-122020-03-04Qifang B, et al.
Observed reproductive number0.4China0.30.52020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to isolation2.7China2.13.32020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to isolation4.6China4.152020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to pcr confirmation3.18China2.653.762020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to pcr confirmation5.46China4.995.922020-01-142020-02-122020-03-04Qifang B, et al.
Basic reproduction number4.8China3.366.672020-01-112020-01-162020-03-03Anastassopoulou C, et al.
Basic reproduction number4.6China3.565.652020-01-112020-01-172020-03-03Anastassopoulou C, et al.
Basic reproduction number5.14China4.256.032020-01-112020-01-182020-03-03Anastassopoulou C, et al.
Basic reproduction number6.09China5.027.162020-01-112020-01-192020-03-03Anastassopoulou C, et al.
Basic reproduction number7.09China5.848.352020-01-112020-01-202020-03-03Anastassopoulou C, et al.
Symptomatic case fatality ratio2.94China2.932020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Recovery rate16China13202020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Infection rate0.191China0.190.1922020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Basic reproduction number2.6ChinaUnspecifiedUnspecified2020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Cumulative case count180000China450007600002020-01-112020-02-292020-03-03Anastassopoulou C, et al.
Basic reproduction number3.25China2.374.142020-01-112020-01-162020-03-03Anastassopoulou C, et al.
Basic reproduction number3.13China2.53.762020-01-112020-01-172020-03-03Anastassopoulou C, et al.
Basic reproduction number3.42China2.913.932020-01-112020-01-182020-03-03Anastassopoulou C, et al.
Basic reproduction number3.96China3.364.572020-01-112020-01-192020-03-03Anastassopoulou C, et al.
Basic reproduction number4.58China3.815.352020-01-112020-01-202020-03-03Anastassopoulou C, et al.
Mortality rate0.147China0.1440.152020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Recovery rate6China572020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Infection rate0.319China0.3180.322020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Basic reproduction number2ChinaUnspecifiedUnspecified2020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Cumulative case count8000000China720000370000002020-01-112020-02-292020-03-03Anastassopoulou C, et al.
Case fatality rate0.8-0.9ChinaUnspecifiedUnspecified2020-01-212020-03-012020-03-03Rui Q, et al.
Case fatality rate5.4ChinaUnspecifiedUnspecified2020-01-212020-03-012020-03-03Rui Q, et al.
Basic reproduction number2.2Cruise Ship2.12.42020-01-202020-02-202020-03-02Zhao S, et al.
Dispersion44Cruise Ship6882020-01-202020-02-202020-03-02Zhao S, et al.
Cumulative case count3066Cruise Ship204634412020-01-202020-02-202020-03-02Zhao S, et al.
Doubling time4.6Cruise Ship39.32020-01-202020-02-202020-03-02Zhao S, et al.
Effective reproduction number1.5South Korea1.41.62020-01-202020-02-262020-03-02Shim E, et al.
Growth rate0.6South Korea0.50.72020-01-202020-02-262020-03-02Shim E, et al.
Cumulative case count79467China71576938552020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count64261China58223778952020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count46607China40812576782020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count13906China12748160922020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1410China132415502020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1265China120413642020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1369China127115592020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1136China105012792020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1100China102112732020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1123China94811462020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count429China3954862020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count356China3343882020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count365China3463932020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count430China4074612020-01-212020-02-142020-02-20Fu X, et al.
Proportion of hospitalized cases admitted to icu0.05ChinaUnspecifiedUnspecified2019-12-312020-02-182020-02-18Zhou G, et al.
Cumulative case count2868.7China1129.74607.72019-12-312020-01-232020-02-18Zhou G, et al.
Cumulative case count52185.4China2056483806.82020-01-232020-02-122020-02-18Zhou G, et al.
Cumulative case count45000ChinaUnspecifiedUnspecified2019-12-312020-02-122020-02-18Wan K, et al.
Basic reproduction number1.44China1.41.472020-01-222020-02-122020-02-18Wan K, et al.
Cumulative case count453ChinaUnspecifiedUnspecified2019-12-082020-01-222020-02-18Zhang B, et al.
Cumulative case count6333ChinaUnspecifiedUnspecified2020-01-232020-02-132020-02-18Zhang B, et al.
Cumulative case count24333ChinaUnspecifiedUnspecified2020-02-14Unspecified2020-02-18Zhang B, et al.
Effective reproduction number3.6ChinaUnspecifiedUnspecified2019-12-082020-01-222020-02-18Zhang B, et al.
Effective reproduction number1.55ChinaUnspecifiedUnspecified2020-01-232020-02-132020-02-18Zhang B, et al.
Effective reproduction number1.08ChinaUnspecifiedUnspecified2020-02-14Unspecified2020-02-18Zhang B, et al.
Cumulative case count7710ChinaUnspecifiedUnspecified2020-01-102020-01-222020-02-18Zhang B, et al.
Cumulative case count18832ChinaUnspecifiedUnspecified2020-01-232020-02-132020-02-18Zhang B, et al.
Cumulative case count21342China21057216292020-02-14Unspecified2020-02-18Zhang B, et al.
Effective reproduction number3.4ChinaUnspecifiedUnspecified2020-01-102020-01-222020-02-18Zhang B, et al.
Effective reproduction number0.83ChinaUnspecifiedUnspecified2020-01-232020-02-132020-02-18Zhang B, et al.
Effective reproduction number0.59ChinaUnspecifiedUnspecified2020-02-14Unspecified2020-02-18Zhang B, et al.
Cumulative case count7793ChinaUnspecifiedUnspecified2020-01-232020-02-032020-02-18Zhang B, et al.
Cumulative case count13384ChinaUnspecifiedUnspecified2020-02-04Unspecified2020-02-18Zhang B, et al.
Effective reproduction number3.3ChinaUnspecifiedUnspecified2020-01-232020-02-032020-02-18Zhang B, et al.
Effective reproduction number0.63ChinaUnspecifiedUnspecified2020-02-04Unspecified2020-02-18Zhang B, et al.
Time from symptom onset to reporting5.1China3.57.52019-12-312020-01-242020-02-17Jung S, et al.
Time from symptom onset to death15.2China13.117.72019-12-312020-01-242020-02-17Jung S, et al.
Cumulative case count6924China488592112019-12-082020-01-242020-02-17Jung S, et al.
Proportion of symptomatics that die5.30%China3.50%7.50%2019-12-082020-01-242020-02-17Jung S, et al.
Basic reproduction number2.1China22.22019-12-082020-01-242020-02-17Jung S, et al.
Cumulative case count19289China10901301582019-12-082020-01-242020-02-17Jung S, et al.
Proportion of symptomatics that die8.40%China5.30%12.30%2019-12-082020-01-242020-02-17Jung S, et al.
Basic reproduction number3.2China2.73.72019-12-082020-01-242020-02-17Jung S, et al.
Cumulative case count4090China397542062019-11-302020-01-112020-02-13Lin Q, et al.
Cumulative case count56833China55242584492019-11-302020-02-092020-02-13Lin Q, et al.
Reporting rate1.41%China1.37%1.45%2019-11-302020-01-112020-02-13Lin Q, et al.
Reporting rate29.74%China28.92%30.60%2019-11-302020-02-092020-02-13Lin Q, et al.
Cumulative case count110000China400003100002020-01-292020-02-022020-02-13Zhao H, et al.
Infection rate1.10%China0.40%3.10%2020-01-292020-02-022020-02-13Zhao H, et al.
Basic reproduction number7.05China6.118.182019-12-312020-01-232020-02-13Mizumoto K, et al.
Effective reproduction number3.24China3.163.322020-01-232020-02-132020-02-13Mizumoto K, et al.
Cumulative case count983006China75957512962582019-12-312020-02-132020-02-13Mizumoto K, et al.
Crude infection fatality ratio0.07%China0.05%0.09%2019-12-312020-02-132020-02-13Mizumoto K, et al.
Time delay adjusted infection fatality ratio0.23%China0.17%0.30%2019-12-312020-02-132020-02-13Mizumoto K, et al.
Proportion of symptomatics that die0.0406ChinaUnspecifiedUnspecified2019-12-312020-02-132020-02-13Mizumoto K, et al.
Cumulative case count3491China192473602019-12-012020-01-222020-02-11Chinazzi M, et al.
Cumulative case count58956China40760874712019-12-012020-01-222020-02-11Chinazzi M, et al.
Ascertainment rate0.1959China0.14360.35582019-12-012020-02-052020-02-11Chinazzi M, et al.
Incubation period4.2China3.55.12019-12-312020-02-102020-02-11Sanche S, et al.
Time from hospitalization to discharge11.5China817.32019-12-312020-02-102020-02-11Sanche S, et al.
Time from hospitalization to death11.2China8.714.92019-12-312020-02-102020-02-11Sanche S, et al.
Growth rate0.29China0.210.372019-12-312020-01-292020-02-11Sanche S, et al.
Cumulative case count4100China242361782019-12-312020-01-182020-02-11Sanche S, et al.
Cumulative case count18700China7141386632020-01-192020-01-232020-02-11Sanche S, et al.
Growth rate0.14China0.120.152020-01-302020-02-102020-02-11Sanche S, et al.
Proportion of symptomatics that die0.18China0.110.812019-12-312020-02-052020-02-10Dorigatt I, et al.
Time from symptom onset to death22.3China18822019-12-312020-01-212020-02-10Dorigatt I, et al.
Cumulative case count24000China13000440002019-12-312020-01-312020-02-10Dorigatt I, et al.
Ascertainment rate0.0012China0.00090.00152020-01-012020-01-222020-02-09Cao Z, et al.
Cumulative case count35454ChinaUnspecifiedUnspecifiedUnspecified2020-01-232020-02-09Cao Z, et al.
Basic reproduction number1.48ChinaUnspecifiedUnspecified2019-12-172020-02-062020-02-08Hermanowic, et al.
Effective reproduction number1.06ChinaUnspecifiedUnspecified2019-12-172020-02-082020-02-08Hermanowic, et al.
Basic reproduction number2.4 – 2.5ChinaUnspecifiedUnspecified2019-12-172020-02-062020-02-08Hermanowic, et al.
Cumulative case count65000ChinaUnspecifiedUnspecified2019-12-172020-02-062020-02-08Hermanowic, et al.
Doubling time2.4ChinaUnspecifiedUnspecified2020-01-202020-02-022020-02-06Muniz-Rodriguez K, et al.
Proportion of hospitalized cases that die33China29372019-12-102020-01-272020-02-04Famular, et al.
Ascertainment rate1China0.622019-12-102020-01-272020-02-04Famular, et al.
Cumulative case count58000ChinaUnspecifiedUnspecified2019-12-312020-01-312020-01-31Gardner L.
Cumulative case count95933ChinaUnspecifiedUnspecified2019-12-312020-01-282020-01-30Ming W, et al.
Cumulative case count31200China23400404002019-12-312020-01-292020-01-29Vespignani A.
Incubation period4.6China3.35.72019-12-312020-01-252020-01-28Linton NM, et al.
Incubation period5China4.15.82019-12-312020-01-252020-01-28Linton NM, et al.
Time from symptom onset to hospitilization2.7China1.64.12019-12-312020-01-252020-01-28Linton NM, et al.
Time from symptom onset to death13.8China11.8162019-12-312020-01-252020-01-28Linton NM, et al.
Time from hospitilization to death8.3China6.410.52019-12-312020-01-252020-01-28Linton NM, et al.
Time from symptom onset to isolation2.9ChinaUnspecifiedUnspecified2019-12-292020-01-232020-01-26Liu T, et al.
Proportion of symptomatics that die0.03ChinaUnspecifiedUnspecified2019-12-292020-01-232020-01-26Liu T, et al.
Incubation period5.4China4.26.72019-12-102020-01-252020-01-26Famular, et al.
Basic reproduction number2.6China1.53.5Unspecified2020-01-182020-01-24Imai N, et al.
Date of emergenceUnspecifiedChina2020-11-192020-12-19UnspecifiedUnspecified2020-01-23Neher R, et al.
Basic reproduction number2.2China1.43.82019-11-272020-01-182020-01-23Riou J, et al.
Basic reproduction numberUnspecifiedChina1.53.52019-11-012020-01-012020-01-23Neher R, et al.
Distribution of secondary cases0.54China0.0146.952019-11-272020-01-182020-01-23Riou J, et al.
Cumulative case count4000China100097002020-01-182020-01-182020-01-22Imai N, et al.

Software Catalog

Listing of software created by community members, with documented metadata. (Click on a software name to open the software webpage.)
software typesoftware nameCreator(s)
VisualizationAlerts for Novel Coronavirus (2019-nCoV)HealthMap
VisualizationNovel Coronavirus (2019-nCoV)Brownstein J, et al.
DashboardDistribution of new coronavirus pneumoniaChina Centers for Disease Control
VisualizationCoronavirus Map: Tracking the Spread of the OutbreakLai R KK, et al.
DashboardCoronavirus COVID-19 Global Cases by Johns Hopkins CSSEGardner L, et al.
VisualizationRealtime interactive map of coronavirus 2019-nCov global distributionMalishev M
DashboardCOVID-19 Surveillance DashboardUniversity of Virignia
DashboardCOVID-19 Cases and Clusters Outside of ChinaUniversity of Virignia
DashboardCOVID-19European Centre for Disease Prevention and Control
DashboardNovel Coronavirus (COVID-19) Infection MapZhao B, et al.
Data processingStats of the ‘2019-nCov’ CasesYu G, et al.
ModelingNobBS: Nowcasting by Bayesian SmoothingMcGough S, et al.
Dashboard2019nCoV-DashboardThe Center for the Ecology of Infectious Diseases (CEID) at the University of Georgia
ModelingA stochastic model for the transmission of 2019-nCov in WuhanThe Center for the Ecology of Infectious Diseases (CEID) at the University of Georgia
ModelingEstimation of the effective reproduction number of COVID-19 outside ChinaThe Center for the Ecology of Infectious Diseases (CEID) at the University of Georgia
ModelingExtended state-space SIR epidemiological modelsSong Lab, et al.
DashboardCOVID-19 Italy – Situation monitoringItalian Department of Civil Protection
Data processingscrapRKucharski A

COVID-19 GitHub Repository

The MIDAS Network has created a GitHub Repository for COVID-19 modeling research. The repository includes data and information, listed on this website, in computational form, mostly structured CSV files and rich metadata.

Directly access content on the COVID-19 GitHub repository:
Published estimates of epidemiological characteristics, encoded by community members and approved by authors.
Listing of software created by community members, with documented metadata.
Reports, pre-prints, and peer-reviewed papers relevant to COVID-19 modeling, organized by country or by topic. All documents are also listed in a downloadable format.

How to Participate

Mailing List:

Any infectious disease scientist, practitioner, or student interested in COVID-19 modeling research can join this mailing list. Subscription requests will be reviewed and approved by a moderator.

Contribute to the MIDAS COVID-19 Repository:

We encourage community members to contribute resources to the repository and thus support the overall COVID-19 research effort. See the information for contributors section on the GitHub repository for guidance on how to contribute material to the repository. Contributions can be made via pull request or by submitting an issue. Contact questions@midasnetwork.us for any questions or ideas for improvements, or to send/request any material to be included.

Join the Slack COVID-19 Workspace:

A Slack workspace is being maintained by Caitlin Rivers (caitlin.rivers@gmail.com). The workspace includes various channels: general, importation, news, random, publications, forecasting, data, and announcements.

Review COVID-19 Preprints on Outbreak Science Rapid PREreview Platform:

This rapid pre-review platform enables the community to give feedback on pre-prints coming out with modeling and other analyses of the COVID-19 and other outbreaks. Visit the platform here.

For questions or concerns, contact the MIDAS Coordination Center via questions@midasnetwork.us.

MIDAS Members Working on COVID-19

Andreas Handel

Associate Professor
University of Georgia, College of Public Health, Department of Epidemiology & Biostatistics

Donald Burke

Distinguished University Professor of Health Science and Policy
University of Pittsburgh

Jin Wang

Professor and UNUM Chair of Excellence
University of Tennessee Chattanooga

M Halloran

Faculty Member
Fred Hutchinson Cancer Research Center

Steven Riley

Professor of Infectious Disease Dynamics
Imperial College London